Urogen Pharma (NASDAQ:URGN - Get Free Report)'s stock price rose 6.8% on Thursday. The company traded as high as $31.83 and last traded at $31.8150. 317,146 shares were traded during mid-day trading, a decline of 64% from the average daily volume of 885,815 shares. The stock had previously closed at $29.79.
Analyst Upgrades and Downgrades
URGN has been the subject of several research analyst reports. TD Cowen upped their price objective on Urogen Pharma from $50.00 to $60.00 and gave the company a "buy" rating in a report on Wednesday, August 5th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Urogen Pharma in a research report on Thursday, October 15th. Jefferies Financial Group reissued a "buy" rating and issued a $56.00 price target on shares of Urogen Pharma in a report on Thursday, September 10th. UBS Group restated an "outperform" rating on shares of Urogen Pharma in a research report on Thursday, November 5th. Finally, Oppenheimer set a $60.00 price objective on shares of Urogen Pharma in a research note on Thursday, November 5th. Eight analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $53.38.
Check Out Our Latest Stock Analysis on URGN
Urogen Pharma Stock Up 7.9%
The business has a 50-day moving average price of $36.10 and a 200-day moving average price of $31.80. The company has a market capitalization of $1.58 billion, a price-to-earnings ratio of -24.31 and a beta of 1.68.
Urogen Pharma (NASDAQ:URGN - Get Free Report) last posted its quarterly earnings data on Wednesday, November 4th. The company reported ($0.03) EPS for the quarter, missing analysts' consensus estimates of $0.11 by ($0.14). The company had revenue of $89.00 million for the quarter, compared to analysts' expectations of $89.92 million. As a group, sell-side analysts predict that Urogen Pharma will post -0.36 EPS for the current year.
Insider Buying and Selling at Urogen Pharma
In other Urogen Pharma news, General Counsel Jason Smith sold 1,519 shares of the company's stock in a transaction that occurred on Tuesday, September 8th. The shares were sold at an average price of $42.54, for a total value of $64,618.26. Following the transaction, the general counsel owned 53,141 shares in the company, valued at approximately $2,260,618.14. This represents a 2.78% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Chris Degnan sold 2,202 shares of the stock in a transaction on Thursday, October 8th. The stock was sold at an average price of $36.69, for a total value of $80,791.38. Following the sale, the chief financial officer owned 4,561 shares of the company's stock, valued at approximately $167,343.09. This represents a 32.56% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 4,592 shares of company stock valued at $182,793 in the last 90 days. 4.80% of the stock is currently owned by corporate insiders.
Institutional Trading of Urogen Pharma
Several large investors have recently added to or reduced their stakes in the business. Aquatic Capital Management LLC bought a new position in shares of Urogen Pharma during the 3rd quarter valued at $40,000. Sterling Capital Management LLC boosted its holdings in Urogen Pharma by 442.1% in the third quarter. Sterling Capital Management LLC now owns 1,339 shares of the company's stock worth $54,000 after purchasing an additional 1,092 shares in the last quarter. C M Bidwell & Associates Ltd. bought a new stake in Urogen Pharma in the third quarter worth $64,000. Persistent Asset Partners Ltd bought a new stake in Urogen Pharma in the second quarter worth $66,000. Finally, Quantbot Technologies LP acquired a new position in Urogen Pharma during the second quarter worth $78,000. 91.29% of the stock is owned by institutional investors.
About Urogen Pharma
(
Get Free Report)
UroGen Pharma Ltd. is a biopharmaceutical company focused on developing and commercializing treatments for cancers of the urinary tract. Its work centers on therapies delivered directly to the urinary system, including treatments for certain forms of urothelial cancer. The company's products include Jelmyto, a mitomycin-based treatment delivered to the upper urinary tract for adults with low-grade upper tract urothelial cancer, and Zusduri, a mitomycin-based treatment for adults with recurrent low-grade, intermediate-risk non-muscle invasive bladder cancer.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Urogen Pharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Urogen Pharma wasn't on the list.
While Urogen Pharma currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.